CD44 and cancer: Comparison of regions T and P indicated that raw SERS signals at 298 cm−1 were significantly greater in T than in P. Raw signals in T and P were significantly attenuated by xenografting with HCT116 cells pretreated with shRNA against CD44, a surface antigen responsible for stabilizing xCT for cancer stemness and survival11,12.